Plasma from healthy donors for frailty and immune health
Part of Immune system & allergy clinical trials.
This Phase 1/2 study tests whether transfusions of donated plasma can improve frailty and immune function in older adults. It mainly checks safety first, and also looks for signs that the immune system and overall strength may improve.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 55 and 95 years old
- Have signs of frailty (based on a frailty score between 4 and 7) or an abnormal immune risk profile
- Be able to get plasma through a vein (need working blood access) and agree to study visits/tests
- Have had no major treatments, radiation, or surgery in the last 4 weeks
- Have blood test results within certain safety ranges (for red cells, white cells, platelets, liver, kidney, and bilirubin)
- Have negative blood tests for certain antibodies that could react to plasma (neutrophil antibodies and specific HLA antibody tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a protein called albumin along with a blood filtering treatment (plasma exchange) can help improve strength and daily function in older adults who feel weak or frail. It aims to see if this combination can reduce frailty and improve quality of life.
This study tests an investigational treatment made from special cells (called mesenchymal stromal cells) that might help reduce frailty in older adults. The treatment is given through an IV and aims to improve strength and overall function.
This study tests a new stem cell medicine given through an IV to see if it is safe for older adults with mild to moderate frailty. Frailty causes weakness and tiredness, and this treatment aims to improve overall health and function.
This study looks at how certain immune system markers, called inflammasomes, relate to frailty (physical weakness and vulnerability) in older adults who are candidates for kidney transplantation. The goal is to better understand these markers, which might help improve care for older transplant patients in the future.
This trial tests a personalized treatment approach for people aged 65 and older with newly diagnosed multiple myeloma. The goal is to tailor therapy based on each patient's level of frailty, which could help improve outcomes and reduce side effects.
This early study (Phase 1) tests whether a lab-made stem cell product given through an IV is safe in people with “aging frailty.” It looks mainly at side effects and safety while also exploring whether the treatment can be given safely.
Hear when a new Frailty trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.